Why Pfizer (PFE) Stock Could Be Your Next Big Win in 2025

Pfizer's stock (PFE) is flashing bullish signals—here's why traders are stacking shares.

Blockbuster Pipeline or Bust?

The pharma giant's late-stage drug roster reads like a Wall Street wishlist. Forget 'enabling' therapies—these candidates slash recovery times and bypass traditional treatment hurdles.

COVID Cash Reinvestment Play

That pandemic windfall wasn't just for executive bonuses (though sure, those too). Pfizer's plowing billions into mRNA platforms that could print money faster than the Fed's money printer.

Dividend Aristocrat with Teeth

While meme-stock degenerates chase vaporware, PFE's been paying dividends since your grandpa's first stock certificate. Yield-hungry investors? This ain't your speculative crypto casino.

The Cynical Take:
If Big Pharma's gonna fleece Americans on drug prices anyway, might as well own the stock. PFE: profiting from pain since 1849.

Image source: Getty Images.

Another issue for Pfizer is that sales of its COVID-19 vaccine and its Paxlovid treatment for COVID-19 are down significantly from earlier levels. Still, though, they're on the market and generating revenue for Pfizer.

Another green flag for Pfizer is its valuation. Its recent forward-looking price-to-earnings (P/E) ratio of 8 is well below its five-year average of 10, and its price-to-sales ratio, recently 2.1, is well below the five-year average of 3.0. So, give this stock some consideration for your long-term portfolio -- especially if you're interested in dividend income.